Second Xiangya Hospital of Central South University

Running trials

• Not yet recruiting

  Remote Intervention Versus Routine Monitoring in COPD Patients With Chronic Hypercapnia Receiving Home Non-invasive Respiratory Support

  NCT07751003· Sir Run Run Shaw Hospital· Source

• Not yet recruiting

  A Study to Learn How Well People With Bronchiectasis Tolerate Continued Treatment With Verducatib After Earlier Studies (AIRTIVITY®-ON)

  NCT07915219· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  Brain Network Mechanisms of Cognitive Impairments in Major Psychiatric Disorders and Their Clinical Applications

  NCT07444463· Central South University· Source

• Not yet recruiting

  Partial Cardiac Denervation for Preventing Atrial Fibrillation After CABG

  NCT07918781· China National Center for Cardiovascular Diseases· Source

• Not yet recruiting

  A Phase I Clinical Trial of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of UBT48128 Tablets in Healthy Participants

  NCT07922798· Phase 1· The United Bio-Technology (Hengqin) Co., Ltd.· Source

• Recruiting

  The Safety and Effectiveness of dTMS for Reducing Antipsychotic-induced Weight Gain

  NCT07795554· Second Xiangya Hospital of Central South University· Source

• Not yet recruiting

  Temporal Interference Stimulation Targeting Thalamus for Schizophrenia-Related Cognitive Dysfunction

  NCT07927790· Central South University· Source

• Recruiting

  tACS for Working Memory in Schizophrenia

  NCT07701343· Central South University· Source

• Not yet recruiting

  hiPSC-CMs-loaded Chitosan Patch to Treat Severe Chronic Ischemic Heart Disease

  NCT07471698· Phase 1/2· HELP Therapeutics Co., Ltd.· Source

• Recruiting

  Finerenone in Patients Undergoing Transcatheter Aortic Valve Implantation With Heart Failure

  NCT07575672· Phase 3· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Recruiting

  A Relation Between Craving Induction and Treatment Response in Deep Transcranial Magnetic Stimulation (dTMS) for Reducing Antipsychotic-induced Weight Gain in Schizophrenia

  NCT07805980· Second Xiangya Hospital of Central South University· Source

• Recruiting

  A Phase 3 Trial for Intravitreal Injection of 4D-150 in Adults With Diabetic Macular Edema (DME).

  NCT07867080· Phase 3· 4D Molecular Therapeutics· Source

• Recruiting

  A Study of ATG-022 Compared With Investigator's Choice of Treatment in Claudin 18.2-Positive Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

  NCT07795346· Phase 3· Antengene Biologics Limited· Source

• Recruiting

  Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)

  NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source

• Recruiting

  Phase III Study of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

  NCT07659574· Phase 3· The United Bio-Technology (Hengqin) Co., Ltd.· Source

• Not yet recruiting

  Rituximab, Pirtobrutinib, Lisaftoclax and Liposomal Mitoxantrone for for Richter Syndrome Transformed From CLL

  NCT07831395· Phase 2· Institute of Hematology & Blood Diseases Hospital, China· Source

• Not yet recruiting

  Clinical Trial of TQA3605 Tablet in Combination With Nucleos(t)Ide Analogues(NAs) Versus NAs Alone for the Treatment of Patients With Chronic Hepatitis B Virus Infection Who Have Undergone Treatment and Exhibit Low Viral Load or Poor Response

  NCT07797231· Phase 3· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Not yet recruiting

  Intraarterial Therapies Plus Tislelizumab Plus Lenvatinib Versus Tislelizumab Plus Gemcitabine-Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

  NCT07691515· Phase 3· Zhejiang Cancer Hospital· Source

• Recruiting

  A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis

  NCT07497087· Phase 3· Boehringer Ingelheim· Source

• Not yet recruiting

  A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease

  NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source

• Recruiting

  The Efficacy and Safety of Inpegsomatropin Injection in Children With Turner Syndrome (TS) and Short Stature

  NCT07614152· Phase 3· Xiamen Amoytop Biotech Co., Ltd.· Source

• Recruiting

  Childhood-onset Lupus Nephritis Initial Glucocorticoid-dose Harmonization Trial (LIGHT Trial)

  NCT07719140· Phase 4· Peking Union Medical College Hospital· Source

• Not yet recruiting

  Brain Functional Connectivity Mechanism of Cognitive Flexibility Impairment and rTMS Intervention in Major Depressive Disorder

  NCT07161492· Second Xiangya Hospital of Central South University· Source

• Recruiting

  A Phase 1b/2a Study of Budoprutug in Systemic Lupus Erythematosus (SLE)

  NCT07564596· Phase 1/2· Climb Bio, Inc.· Source

• Recruiting

  TIS for Improving Cognitive Impairment in Schizophrenia

  NCT07647380· Central South University· Source

• Recruiting

  A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)

  NCT07554339· Phase 3· Merck Sharp & Dohme LLC· Source

• Not yet recruiting

  Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial 2.0

  NCT07682415· Phase 2· Yi Shuhua· Source

• Not yet recruiting

  Mechanisms of Sulforaphane Supplementation in Alleviating Negative Symptoms and Cognitive Impairment in Schizophrenia

  NCT07652866· Second Xiangya Hospital of Central South University· Source

• Recruiting

  Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung Cancer

  NCT07886229· Phase 1· Second Xiangya Hospital of Central South University· Source

• Recruiting

  Propranolol Hydrochloride Combined With Adebrelimab and Platinum-Based Chemotherapy in Small Cell Lung Cancer

  NCT07886047· Phase 1· Second Xiangya Hospital of Central South University· Source

• Recruiting

  A Study to Compare the PK Characteristics, Safety, Tolerability, and Immunogenicity of HLX15-SC With DARZALEX FASPRO® in Combination With Lenalidomide and Dexamethasone (Rd) in Transplant-ineligible Patients With Newly Diagnosed Multiple Myeloma

  NCT07477587· Phase 1· Shanghai Henlius Biotech· Source

• Recruiting

  Phase II Clinical Trial to Evaluate the Efficacy and Safety of SYH2070 Injection in Participants With Homozygous Familial Hypercholesterolemia

  NCT07591298· Phase 2· CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.· Source

• Recruiting

  A Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease

  NCT07577843· Phase 3· Janssen Research & Development, LLC· Source

• Recruiting

  Study on iTBS Regulating the Reward Circuit Function to Improve Anhedonia in Depression

  NCT07813169· Guo Wenbin· Source

• Recruiting

  Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation

  NCT07444372· Beijing Anzhen Hospital· Source

• Recruiting

  A Master Protocol (IIBD): A Study of Multiple Drugs in Adults With Ulcerative Colitis or Crohn's Disease

  NCT07483073· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of LY4395089 and Mirikizumab (LY3074828) Given Together and Mirikizumab (Alone) in Adults With Crohn's Disease

  NCT07483099· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Phase Ⅰb/Ⅱa Clinical Study of IMC-003 Injection for the Treatment of Pulmonary Arterial Hypertension Receiving Background Therapy.

  NCT07593027· Phase 1/2· ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.· Source

• Recruiting

  A Clinical Study of Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

  NCT07338487· Phase 1· Second Xiangya Hospital of Central South University· Source

• Recruiting

  A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer

  NCT07474727· Phase 2· Multitude Therapeutics Inc.· Source

• Recruiting

  A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

  NCT07419295· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  A Study of E6742 in Participants With Systemic Lupus Erythematosus

  NCT07515014· Phase 2· Eisai Co., Ltd.· Source

• Recruiting

  A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

  NCT07326709· Phase 3· Novartis Pharmaceuticals· Source

• Recruiting

  A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCL

  NCT07409428· Phase 3· Hutchmed· Source

• Recruiting

  HARMONY Trial : To Evaluate a Therapeutic and Monitoring Device(NOVAtria System) for Heart Failure Management

  NCT07402239· United Innomed(Shanghai) Limited· Source

• Recruiting

  ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

  NCT06951646· Phase 2· Second Xiangya Hospital of Central South University· Source

• Not yet recruiting

  A Clinical Study to Evaluate Injection TQB2102 for the Treatment of Patients With HER2 IHC3+ Advanced Colorectal Cancer Who Progressed After Treatment With Oxaliplatin, Irinotecan and Fluoropyrimidine-Based Drugs

  NCT07483684· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

  NCT07363694· Phase 2/3· Pfizer· Source

• Recruiting

  A Study of Brenipatide in Adult Participants With Schizophrenia

  NCT07410507· Phase 2· Eli Lilly and Company· Source

• Recruiting

  A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin

  NCT07392190· Phase 3· Eli Lilly and Company· Source

Showing 50 of 217.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer21 recruiting
• Schizophrenia9 recruiting
• Type 1 diabetes9 recruiting
• Crohn's disease8 recruiting
• Heart failure8 recruiting
• Chronic lymphocytic leukaemia7 recruiting
• Bronchiectasis5 recruiting
• Obesity5 recruiting
• Type 2 diabetes5 recruiting
• Coronary artery disease4 recruiting
• Depression4 recruiting
• Hepatitis B4 recruiting
• Lupus (SLE)4 recruiting
• Asthma3 recruiting
• Atopic dermatitis (eczema)3 recruiting
• Cervical cancer3 recruiting
• Childhood cancers3 recruiting
• Colorectal cancer3 recruiting
• COPD3 recruiting
• Diffuse large B-cell lymphoma3 recruiting
• Gastric and oesophageal cancer3 recruiting
• Head and neck cancer3 recruiting
• High blood pressure3 recruiting
• Aortic stenosis2 recruiting
• Atrial fibrillation2 recruiting
• Autism2 recruiting
• Bipolar disorder2 recruiting
• Diabetic eye disease2 recruiting
• Familial hypercholesterolaemia2 recruiting
• Fatty liver disease (MASLD/MASH)2 recruiting
• Liver and biliary tract cancer2 recruiting
• Metastatic breast cancer2 recruiting
• Osteoporosis2 recruiting
• Pancreatic cancer2 recruiting
• Pulmonary arterial hypertension2 recruiting
• Systemic sclerosis (scleroderma)2 recruiting
• Ulcerative colitis2 recruiting
• Acute lymphoblastic leukaemia1 recruiting
• Amyloidosis1 recruiting
• Bladder cancer1 recruiting
• Congenital heart disease1 recruiting
• Dermatomyositis and polymyositis (myositis)1 recruiting
• Endometrial cancer1 recruiting
• Follicular lymphoma1 recruiting
• Hearing loss1 recruiting
• Hidradenitis suppurativa1 recruiting
• Huntington's disease1 recruiting
• Idiopathic pulmonary fibrosis1 recruiting
• Liver cirrhosis1 recruiting
• Macular degeneration1 recruiting
• Mantle cell lymphoma1 recruiting
• Migraine1 recruiting
• Multiple myeloma1 recruiting
• Neuromyelitis optica (NMOSD)1 recruiting
• Obstructive sleep apnoea1 recruiting
• Ovarian cancer1 recruiting
• Rheumatoid arthritis1 recruiting
• Sjögren's disease1 recruiting
• Stroke1 recruiting
• Triple-negative breast cancer1 recruiting
• Turner syndrome1 recruiting
• Ventricular tachycardia1 recruiting
• Vitiligo1 recruiting

Closed trials

• Completed

  TIS for Improving Cognitive Impairment Associated With Schizophrenia

  NCT07446478· Central South University· Source

• Completed

  A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

  NCT07357831· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  Baduanjin With Resistance Training Program

  NCT06853132· Yale University· Source

• Terminated

  A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis

  NCT07100938· Phase 2· BeiGene· Source

• Completed

  A Study to Evaluate the Efficacy, Safety, and Pharmacokinetic Characteristics of (R)-Ketamine Hydrochloride Nasal Spray in Patients With Depression and Acute Suicidal Ideation or Behavior

  NCT07193901· Phase 2· Sichuan Purity Pharmaceutical Technology Co., Ltd.· Source

• Terminated

  Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer

  NCT06897579· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  UBT251 Injection Phase II Study (Overweight or Obesity)

  NCT07177469· Phase 2· The United Bio-Technology (Hengqin) Co., Ltd.· Source

• Completed

  A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

  NCT06723652· Phase 3· Beijing Suncadia Pharmaceuticals Co., Ltd· Source

• Completed

  Efficacy and Safety of Roflumilast Cream in Subjects With Atopic Dermatitis

  NCT06631170· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection

  NCT06644417· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source

• Completed

  Efficacy and Safety of Roflumilast Cream 0.3% in Subjects With Plaque Psoriasis: a Phase 3 Study

  NCT06648772· Phase 3· Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.· Source

• Completed

  A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (PAH) (MK-7962-024)

  NCT06664801· Phase 2· Merck Sharp & Dohme LLC· Source

• Completed

  the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Diet and Exercise Alone

  NCT06650007· Phase 3· Fujian Shengdi Pharmaceutical Co., Ltd.· Source

• Completed

  To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis

  NCT06552520· Phase 3· Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.· Source

• Withdrawn

  Mechanism Study of Sulforaphane in ASD Improvement

  NCT07047976· Jian-Jun Ou· Source

• Completed

  A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT06335303· Phase 2· Boehringer Ingelheim· Source

• Completed

  Effects of Berberine Ursodeoxycholate (HTD1801) Versus Dapagliflozin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin

  NCT06415773· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source

• Completed

  A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema

  NCT06422507· Phase 3· Bayer· Source

• Recruiting

  A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)

  NCT06345729· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis

  NCT06280716· Phase 3· Eli Lilly and Company· Source

• Completed

  The Validation and Biological Index Studies on the Improved Social Function of ASD by 40 Hz tACS

  NCT06362200· Central South University· Source

• Completed

  Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine

  NCT06241313· Phase 3· AbbVie· Source

• Completed

  Comparison of a Single Versus Double Perclose Technique for TAVR

  NCT06173115· Second Affiliated Hospital, Zhejiang University, School of Medicine· Source

• Completed

  Evaluate the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial Hypercholesterolemia

  NCT06009393· Phase 2· Beijing Suncadia Pharmaceuticals Co., Ltd· Source

• Completed

  A Study to Investigate Efficacy and Safety of Apremilast 30 mg Twice Daily (BID) in Chinese Participants With Moderate to Severe Plaque-type Psoriasis (PsO)

  NCT06122649· Phase 3· Amgen· Source

• Completed

  A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension

  NCT06137742· Phase 1/2· Pfizer· Source

• Terminated

  Randomized, Double-blind Study of Efficacy and Safety of Bexotegrast (PLN-74809) for Idiopathic Pulmonary Fibrosis

  NCT06097260· Phase 2· Pliant Therapeutics, Inc.· Source

• Completed

  A Study of Gimistotug (BGB-A445) in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer

  NCT06029127· Phase 2· BeiGene· Source

• Completed

  Tobramycin Inhalation Solution for Pseudomonas Aeruginosa Eradication in Bronchiectasis

  NCT06093191· Phase 4· Jin-Fu Xu· Source

• Completed

  A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis

  NCT06049017· Phase 2· Janssen Research & Development, LLC· Source

• Withdrawn

  A Novel Application of 2% Lidocaine Injection for Male Rigid cycstoscopy-a Patient-blinded Randomised Trial

  NCT06301308· Phase 3· Second Xiangya Hospital of Central South University· Source

• Completed

  Robotic Natural Orifice Specimen Extraction Surgery Versus Robotic Transabdominal Specimen Extraction Surgery for Early-Stage Rectal Cancer

  NCT06405308· Taiyuan Li· Source

• Completed

  A Clinical Study to Evaluate the Efficacy and Safety of Subcutaneous JS005 Injection in the Treatment of Adults With Moderate to Severe Chronic Plaque Psoriasis

  NCT05975268· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source

• Completed

  A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

  NCT05909904· Phase 2· BeiGene· Source

• Completed

  Neuroregulatory Effect and Mechanism of tDCS on Medial Prefrontal Cortex in ASD

  NCT06305988· Jian-Jun Ou· Source

• Completed

  Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM

  NCT05767346· Phase 3· Cytokinetics· Source

• Completed

  Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05938920· Phase 2· InSilico Medicine Hong Kong Limited· Source

• Completed

  AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia

  NCT07030595· Phase 3· Alebund Pharmaceuticals· Source

• Completed

  A Study to Assess the Efficacy and Safety of KarXT in Acutely Psychotic Hospitalized Chinese Adult Subjects With DSM-5 Schizophrenia

  NCT05919823· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

• Completed

  Efficacy, Safety, and Acceptability of Internet-based Cognitive Behavioral Therapy

  NCT05554289· Adai Technology (Beijing) Co., Ltd.· Source

• Completed

  HPP737 in Adult Patients With Moderate-to-severe Plaque Psoriasis.

  NCT07712705· Phase 3· Newsoara Biopharma Co., Ltd.· Source

• Completed

  Lunsayil 1: A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa

  NCT05819398· Phase 2/3· Boehringer Ingelheim· Source

• Completed

  A Phase III Study for 601 Versus Ranibizumab in Patients With Vision Loss

  NCT05520177· Phase 3· Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.· Source

• Completed

  A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

  NCT05550532· Phase 3· Janssen Research & Development, LLC· Source

• Completed

  A Study to Evaluate Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis

  NCT05601882· Phase 3· AbbVie· Source

• Completed

  A Study to Evaluate the Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

  NCT05531682· Phase 2· Huabo Biopharm Co., Ltd.· Source

• Completed

  iTBS on Negative Symptoms and Cognitive Function in Schizophrenia

  NCT05137158· Central South University· Source

• Completed

  A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.

  NCT05523167· Phase 2/3· argenx· Source

• Completed

  A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

  NCT05321069· Phase 3· Boehringer Ingelheim· Source

• Completed

  A Study of Insulin Efsitora Alfa (LY3209590) Compared to Degludec in Adults With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time

  NCT05362058· Phase 3· Eli Lilly and Company· Source

Showing 50 of 79.

Conditions

Diseases this institution publishes on or runs trials for.

• Depression55 works · 9 trials
• Schizophrenia47 works · 15 trials
• COPD42 works · 5 trials
• Lupus (SLE)39 works · 9 trials
• Bipolar disorder37 works · 3 trials
• Osteoporosis35 works · 4 trials
• Insomnia33 works · 1 trial
• Fatty liver disease (MASLD/MASH)26 works · 3 trials
• Type 1 diabetes25 works · 9 trials
• Aortic aneurysm21 works · 0 trials
• Pulmonary arterial hypertension18 works · 5 trials
• Glaucoma18 works · 0 trials
• Atopic dermatitis (eczema)17 works · 10 trials
• Myasthenia gravis12 works · 0 trials
• Hepatitis B10 works · 10 trials
• IgA nephropathy8 works · 2 trials
• High blood pressure6 works · 9 trials
• Neuromyelitis optica (NMOSD)6 works · 1 trial
• Multiple system atrophy5 works · 0 trials
• Essential tremor3 works · 0 trials